J&J buys eye-disease biotech Ollin for $2.2 billion, up to $3.33 billion with milestones
Johnson & Johnson is paying $2.2 billion upfront for Ollin Biosciences, adding an experimental retinal drug in an area where it has little presence outside contact lenses. Blackstone will fund late-stage development.
Johnson & Johnson said on Monday it has agreed to buy Texas-based Ollin Biosciences for up to $3.33 billion, according to CNBC. The price is $2.2 billion upfront plus up to about $1.13 billion in regulatory and commercial milestone payments. The deal is expected to close before the end of 2026.
The Financial Times reported the talks late Sunday, putting the possible value at up to $3.4 billion, as carried by Reuters on Investing.com. The announced figure came in slightly lower.
What J&J is getting
The asset is OLN324, an experimental drug for diabetic macular edema and wet age-related macular degeneration, two leading causes of vision loss. Ollin describes it as a drug that targets two drivers of retinal disease, and trade press describes it as a bispecific antibody aimed at VEGF and angiopoietin-2 (Contract Pharma).
Ollin says an early-stage head-to-head study showed faster and greater improvements in eye structure, and greater vision gains, than Roche's Vabysmo in both conditions. That is the company's own characterization of early data, not a late-stage result, and the drug has not yet been through the larger trials that decide whether such results hold. Ollin has said it plans to start late-stage studies in the second half of this year and raised $330 million in June to fund them. A second program, OLN102, is in preclinical development for thyroid eye disease and Graves' disease.
The structure matters more than the headline
Roughly a third of the headline value, about $1.13 billion of $3.33 billion, is contingent on milestones. The cash J&J commits at signing is the $2.2 billion.
J&J also said it will sign a separate agreement with Blackstone Life Sciences. Blackstone will pay J&J $750 million over several years to fund late-stage development of OLN324 and will be eligible to receive payments and royalties in return. Put simply, an outside investor is carrying a share of the trial costs, which lowers what J&J spends before it knows whether the drug works, in exchange for a slice of the upside. Reuters noted that last week Pfizer said Blackstone would provide up to $1.5 billion through 2028 toward an experimental monthly obesity treatment, so this is a second large drugmaker-Blackstone arrangement in a week.
The deal expands J&J's presence in ophthalmology, a field where, as CNBC put it, it has a limited footprint despite its large contact lens business. Ollin was founded in 2023 and backed by ARCH Venture Partners and Mubadala Capital.
What to watch
- Whether the deal closes before year end, as J&J expects.
- The start of late-stage trials for OLN324, the first real test of the early comparison with Vabysmo.
- Further drugmaker-financier funding deals like the Blackstone arrangements, which shift development risk off the big company's balance sheet.
For readers following the shares, J&J's last close in our chart data was $285.75 on Nov. 13; the stock has not yet been checked against its Monday trading in this report.
Sources: CNBC; Reuters via Investing.com; Contract Pharma. This is market information, not investment advice.
Want your business to be the answer?
Get a full package of articles about your business, built so customers, Google and AI assistants can find you.
New ebook from The Company ChronicleHow to Research Like a Wall Street AnalystFind original sources, analyze trends, and build your own insights. 36 pages with worksheets.Get the ebook · $29Instant PDF download

